Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels
Makaleler > Tam Makale · 2012
Yazarlar: Asli Kisim, Harika Atmaca, Burcu ÇAKAR, BÜLENT KARABULUT, Canfeza SEZGIN, Selim Uzunoglu, RÜÇHAN USLU, Burcak Karaca
Journal of Cancer Research and Clinical Oncology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2012, cilt 138, ss 1155-1163
DOI: 10.1007/s00432-012-1187-1
Özet
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and has been shown to induce extrinsic pathway of apoptosis in many types of cancer cells. AT-101, an (-)-enantiomer of gossypol, is a potent anticancer agent that is shown to be an inhibitor of Bcl-2/Bcl-XL. In this study, we searched whether pretreatment with either of these drugs would result in the enhancement of apoptosis through induction of death receptors and activation of mitochondrial pathways within breast cancer cells.